Background: Biomarkers of combination with immunotherapy therapy remains unknown. To explore prediction of efficacy in patients(pts) with non small cell lung cancer (NSCLC) without driver genes mutations which received Camrelizumab combined with chemotherapy. Methods: From Jan, 2020 to Dec, 2021, 28 pts with NSCLC without driver genes mutations who received Camrelizumab combined with chemotherapy for 4 cycles. According to RECIST1.1, all of these patients were assessed with benefit. IFN, TNF-α, IL (IL-1B、IL-2、IL-4、IL5、IL-6、IL-8、IL-10、IL-12P70、IL-17)in peripheral blood of all pts were measured using flow cytometry. Statistical analyses were performed with SPSS 23.0 software (Pearson’s correlation). Results: Before treatment, the mean values of IFN-α, IFN-γ, TNF-α and IL in pts with partial response (PR) were higher than in pts with stable disease (SD). There was no correlation with age, sex, stage and pathological type of pts (P > 0.05). There was significant difference of IFN- α, IL-1B, IL-5 and IL-6 increased compared with the level before treatment in 28 pts (P＜0.05). However, pts with PR compared with pts with SD, There were no significant differences of IFN-α, IFN-γ, TNF-α, IL compared with the level before treatment (P > 0.05). The IFN-α, IL-1B, IL-5, IL-6 Spearman correlation showed that before treatment, there was a correlation between INF-α and IL-5, INF-α and IL-1B, INF- α and IL-6, IL-1B and IL-6, respectively (r = 0.786, P = 0.036 < 0.05; r = 0.889, P = 0.007 < 0.05; r = 0.929, P = 0.003 < 0.05; r = 0.778, P = 0.039 < 0.05). In self-control before and after treatment, there was a correlation between INF-α and IL-1B, INF- α and IL-6, IL-1B and IL-6, respectively (r = 0.880, P = 0.009 ＜05; r = 0.936, P = 0.002＜ 0.05; r = 0.882, P = 0.023＜ 0.05). Conclusions: First-line chemotherapy combined with Camrelizumab in NSCLC without driver genes mutations can effectively improve the levels of IFN-α, IL-1B, IL-5, and IL-6, and the combined detection has certain predictive significance for the efficacy evaluation of patients. Further study is needed.